anonymous
Guest
anonymous
Guest
It's remarkable how reactive Regeneron was during launch of Praluent. Not an original thought as the company positioned itself vs. the payers and competed with Repatha. Most recently, the head in the sand approach to Inclisiran entering the market.
So long folks, it's been real, Let the 3 directors bend over and continue taking it hard; perhaps a bold stance to a change in message would have been appropriate, no? Big pharma call counts create BS data...Duh!
I feel bad for the hardworking sales teams that stuck with it. Talk about a lump of coal for Christmas.
Thoughts?
So long folks, it's been real, Let the 3 directors bend over and continue taking it hard; perhaps a bold stance to a change in message would have been appropriate, no? Big pharma call counts create BS data...Duh!
I feel bad for the hardworking sales teams that stuck with it. Talk about a lump of coal for Christmas.
Thoughts?